Cytotoxic Imidazopyridine Compounds and Their Use in Therapy
Summary
The USPTO granted Patent US12599676B2 to MyricX Pharma Limited for cytotoxic imidazo[1,2-A]pyridine compounds and their therapeutic use. The patent covers compounds of formula (I) classified under A61P 35/00 for cancer therapy. The application (19072750) was filed March 6, 2025, and the patent contains 23 claims.
What changed
The USPTO issued Patent US12599676B2 granting MyricX Pharma Limited exclusive rights to cytotoxic imidazo[1,2-A]pyridine compounds for therapeutic applications. The patent includes compounds classified under A61P 35/00 (antineoplastic agents) with CPC classifications spanning A61K 47/6851, A61K 47/6803, and C07K 16/32.
Pharmaceutical companies and research institutions developing cancer therapies should review this patent to assess potential licensing needs or freedom-to-operate considerations for imidazopyridine-based compounds. The patent grants MyricX Pharma Limited 20-year exclusivity from the filing date.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy
Grant US12599676B2 Kind: B2 Apr 14, 2026
Assignee
MyricX Pharma Limited
Inventors
Robin Carr, Roberto Solari, Andrew Simon Bell, Edward William Tate, Roger Bonnert
Abstract
The present invention relates to compounds of formula (I) and related aspects.
CPC Classifications
A61K 47/6851 A61K 47/6803 C07K 16/32 A61P 35/00
Filing Date
2025-03-06
Application No.
19072750
Claims
23
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.